This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Motus GI Holdings Gestione

Gestione criteri di controllo 3/4

Motus GI Holdings' CEO is Mark Pomeranz, appointed in Apr 2023, has a tenure of less than a year. total yearly compensation is $515.51K, comprised of 74.7% salary and 25.3% bonuses, including company stock and options. directly owns 0.01% of the company’s shares, worth €134.88. The average tenure of the management team and the board of directors is 0.6 years and 5.5 years respectively.

Informazioni chiave

Mark Pomeranz

Amministratore delegato

US$515.5k

Compenso totale

Percentuale dello stipendio del CEO	74.7%
Mandato del CEO	less than a year
Proprietà del CEO	0.009%
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	5.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Mark Pomeranz rispetto agli utili di Motus GI Holdings?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2023	n/a	n/a	-US$14m
Jun 30 2023	n/a	n/a	-US$16m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$516k	US$385k	-US$19m
Sep 30 2022	n/a	n/a	-US$20m
Jun 30 2022	n/a	n/a	-US$20m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$858k	US$385k	-US$25m
Sep 30 2021	n/a	n/a	-US$25m
Jun 30 2021	n/a	n/a	-US$24m
Mar 31 2021	n/a	n/a	-US$24m
Dec 31 2020	US$825k	US$385k	-US$19m
Sep 30 2020	n/a	n/a	-US$21m
Jun 30 2020	n/a	n/a	-US$22m
Mar 31 2020	n/a	n/a	-US$23m
Dec 31 2019	US$1m	US$385k	-US$23m
Sep 30 2019	n/a	n/a	-US$23m
Jun 30 2019	n/a	n/a	-US$23m
Mar 31 2019	n/a	n/a	-US$21m
Dec 31 2018	US$502k	US$359k	-US$22m
Sep 30 2018	n/a	n/a	-US$20m
Jun 30 2018	n/a	n/a	-US$18m
Mar 31 2018	n/a	n/a	-US$18m
Dec 31 2017	US$2m	US$350k	-US$13m

Compensazione vs Mercato: Mark's total compensation ($USD515.51K) is about average for companies of similar size in the German market ($USD407.69K).

Compensazione vs guadagni: Mark's compensation has been consistent with company performance over the past year.

AMMINISTRATORE DELEGATO

Mark Pomeranz (61 yo)

less than a year

Mandato

US$515,505

Compensazione

Mr. Mark Pomeranz serves as Chief Executive Officer of Motus GI Holdings, Inc. since April 13, 2023. He had been President and Chief Operating Officer of Motus GI Holdings Inc. since September 24, 2018 unt...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Mark Pomeranz	Non-Independent Director & CEO	less than a year	US$515.51k	0.0095% $ 134.9
Ravit Ram	CFO & VP of Global Operations	less than a year	Nessun dato	0% $ 0
Elad Amor	Chief Accounting Officer	less than a year	Nessun dato	0% $ 0

0.6yrs

Durata media

Gestione esperta: 7M4's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Mark Pomeranz	Non-Independent Director & CEO	8yrs	US$515.51k	0.0095% $ 134.9
Steven Edmundowicz	Member of Medical Advisory Board	no data	Nessun dato	Nessun dato
David Lieberman	Member of Medical Advisory Board	no data	Nessun dato	Nessun dato
Gary John Pruden	Independent Director	6.1yrs	US$73.84k	0.048% $ 676.4
Scott Durbin	Director	less than a year	Nessun dato	Nessun dato
Seth Gross	Member of Advisory Board	5.7yrs	Nessun dato	Nessun dato
Sonja Nelson	Independent Director	2.6yrs	US$62.29k	0.022% $ 307.4
Ian Gralnek	Member of Medical Advisory Board	no data	Nessun dato	Nessun dato
Brian Jacobson	Member of Medical Advisory Board	no data	Nessun dato	Nessun dato
Peter Siersema	Member of Medical Advisory Board	no data	Nessun dato	Nessun dato
Gerald Bertiger	Member of Medical Advisory Board	no data	Nessun dato	Nessun dato
Timothy Moran	Independent Chairman	5.3yrs	US$683.60k	0.032% $ 453.3

5.5yrs

Durata media

54yo

Età media

Consiglio di amministrazione esperto: 7M4's board of directors are considered experienced (5.5 years average tenure).

This company listing is no longer active

Motus GI Holdings Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Motus GI Holdings, Inc. Announces Executive Changes

Motus GI Holdings, Inc., Annual General Meeting, Sep 21, 2023

Shervin Korangy Resigns from the Board of Directors of Motus GI Holdings, Inc

Motus GI Holdings, Inc. Announces Executive Changes

Insufficient new directors

Motus GI Holdings, Inc., Annual General Meeting, Jun 30, 2022

Recent updates

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from S&P TMI Index

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from NASDAQ Composite Index

Motus GI Holdings Receive Non-Compliance Letter from Nasdaq Related to Listing Rule 5550(a)(2)

Motus GI Holdings, Inc. Publishes Positive Results from A European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with A History of Poor Bowel Preparation

Motus GI Holdings, Inc. Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu®? EVS Gastro

Motus GI Holdings, Inc. Receives Fda Clearance to Commercialize Pure-Vu Evs Gastro and Gen 4 Colon

Motus GI Holdings Announces Update on Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Motus GI Holdings, Inc. Announces Executive Changes

New major risk - Financial position

Second quarter 2023 earnings released: US$0.40 loss per share (vs US$1.86 loss in 2Q 2022)

Motus GI Holdings, Inc. Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of Its Pure-Vu® EVS System

Motus GI Holdings, Inc., Annual General Meeting, Sep 21, 2023

Shervin Korangy Resigns from the Board of Directors of Motus GI Holdings, Inc

Motus GI Holdings Provides Shareholder's Equity Compliance Update

Motus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 At the Pentax Learning Center

Motus GI Holdings, Inc. Announces Executive Changes

Motus GI Holdings, Inc. announced that it expects to receive $3.5 million in funding

Motus GI Holdings, Inc. Completes First Clinical Evaluation of New Pure-Vu(R) Gastro in Upper Gastrointestinal Procedures to Support Fda Submission

First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.86 loss in 1Q 2022)

Motus GI Holdings Receives Non-Compliance Notice From Nasdaq

Motus GI Holdings, Inc. Announces Improvement of Pure-Vu® EVS System for Use in Upper Gastrointestinal (GI) Bleeding Procedures Following Successful Pre-Clinical Tests

Insufficient new directors

Motus GI Holdings, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Second quarter 2022 earnings released: US$1.86 loss per share (vs US$1.99 loss in 2Q 2021)

Motus GI Regains Compliance with Nasdaq Minimum Bid Price Requirement

Motus GI Holdings, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings, Inc., Annual General Meeting, Jun 30, 2022

First quarter 2022 earnings released: US$0.093 loss per share (vs US$0.26 loss in 1Q 2021)

Insufficient new directors

Motus GI Completes Enrollment in the European Union Feasibility Study of the Pure-Vu System as a New Method for Bowel Cleansing in Patients with a History of Poor Bowel Preparation

Full year 2021 earnings released: US$0.54 loss per share (vs US$0.60 loss in FY 2020)

Motus GI Grants 180-Day Extension to Meet NASDAQ Minimum Bid Price Requirement

Motus GI Holdings, Inc. Receives FDA Clearance to Market the Pure-Vu® EVS System

Third quarter 2021 earnings released: US$0.10 loss per share (vs US$0.13 loss in 3Q 2020)

Insufficient new directors

Independent Director Samuel Nussbaum has left the company

Second quarter 2021 earnings released: US$0.099 loss per share (vs US$0.15 loss in 2Q 2020)

Motus GI Announces First Patients Enrolled in the European Union Feasibility Study of the Pure-Vu® System as a New Method for Bowel Cleansing in Patients With a History of Poor Bowel Preparation

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.23 loss in 1Q 2020)

Forecast to breakeven in 2025

Motus Gi Holdings, Inc. Announces Publication of A Pure-Vu System® Cost Effectiveness Analysis in the Journal of Cost Effectiveness and Resource

Motus GI Receives FDA Clearance to Market the Pure-Vu® System for Upper GI Endoscopy

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media